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Abstract
Objective: We aimed to mine the data in the Electronic Medical Record to automatically discover patients’ Rheumatoid
Arthritis disease activity at discrete rheumatology clinic visits. We cast the problem as a document classification task where
the feature space includes concepts from the clinical narrative and lab values as stored in the Electronic Medical Record.
Materials and Methods: The Training Set consisted of 2792 clinical notes and associated lab values. Test Set 1 included
1749 clinical notes and associated lab values. Test Set 2 included 344 clinical notes for which there were no associated lab
values. The Apache clinical Text Analysis and Knowledge Extraction System was used to analyze the text and transform it
into informative features to be combined with relevant lab values.
Results: Experiments over a range of machine learning algorithms and features were conducted. The best performing
combination was linear kernel Support Vector Machines with Unified Medical Language System Concept Unique Identifier
features with feature selection and lab values. The Area Under the Receiver Operating Characteristic Curve (AUC) is 0.831
(s= 0.0317), statistically significant as compared to two baselines (AUC= 0.758, s= 0.0291). Algorithms demonstrated
superior performance on cases clinically defined as extreme categories of disease activity (Remission and High) compared to
those defined as intermediate categories (Moderate and Low) and included laboratory data on inflammatory markers.
Conclusion: Automatic Rheumatoid Arthritis disease activity discovery from Electronic Medical Record data is a learnable
task approximating human performance. As a result, this approach might have several research applications, such as the
identification of patients for genome-wide pharmacogenetic studies that require large sample sizes with precise definitions
of disease activity and response to therapies.
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Introduction
Long-term outcome in patients with rheumatoid arthritis (RA) is
highly dependent upon an aggressive pharmacological control of
inflammation early in the disease course. Despite the importance
of selecting the optimal medication soon after disease onset, there
is no reliable biomarker predictor of drug treatment response. As a
consequence, RA patients often suffer irreversible joint destruction
while a physician searches for an effective drug. Disease activity
modifying anti-rheumatic drugs (DMARDS) are considered first-
line therapy for RA while new biologic agents, such as drugs that
block the inflammatory cytokine TNF-alpha are considered highly
effective yet induce remission in only 30% of patients [1,2,3,4,5].
The choice of drug therapy is based on disease activity levels and
clinical prognostic features. A genetic biomarker that associates
with high likelihood of biologic agent response could change this
paradigm, and improve outcomes in early RA.
Disease activity assessed at clinical visits drives the choice of
therapy. Standardized disease activity levels are measured at
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regular intervals as the primary endpoint in RA clinical trials.
However, defining disease activity before and after drug exposure
in observational Electronic Medical Record (EMR) data is
challenging, as clinicians typically do not regularly code disease
activity in structured fields but describe it as free text in the clinical
narrative. For example, at our institution, we have a structured
disease activity tool [6] and a longitudinal cohort study [7] that
collect disease activity data at individual patient visits, but these
structured data are available on a minority of visits (20–30%).
One example of a structured tool used by Partners HealthCare
is the Disease Activity Score in 28 joints (DAS28) tool scored by
study rheumatologists for RA patients followed annually in a
cohort study, the Brigham&Womens Rheumatoid Arthritis
Sequential Study (BRASS), and clinical rheumatologists for RA
patients. DAS28 is a composite index developed and validated for
use in clinical trials. It is based on weighted variables for swollen
joint count, tender joint count, the C-reactive protein level (CRP)
or erythrocyte sedimentation rate (ESR), and patient-reported
assessment of global health. The original DAS algorithm was
developed from clinical and laboratory variables assessed by six
rheumatologists in a prospective study of three years’ duration.
They defined high, moderate, low and remission disease activity
based on associations with changes in medication [8]. Once the
DAS algorithm was developed, it was validated in additional RA
patients [9], and eventually applied to thousands of patients in
clinical trials, patient registries and routine office visits. Remark-
ably, the original analysis was performed in only 113 RA patients
in the 1980’s, prior to the introduction of biological DMARDs;
nonetheless, the essential components of the algorithm are in use
today.
However, the majority of the disease activity information is not
created through structured tools; rather, it is scattered as free text
descriptions throughout the clinical narrative within the EMR.
Over the past decade, many natural language processing (NLP)
systems have been utilized in various types of healthcare EMR
applications [10,11,12,13,14,15,16,17] to process the clinical
narrative and extract relevant information from it. There are
tools built for specific tasks such as SymText utilized in identifying
pneumonia-related concepts and finding pneumonia-supported
reports [13,14]. The Unified Medical Language System (UMLS)
[18] is frequently used as a source of ontology codes, for example
the terms rheumatoid arthritis and RA are assigned the same UMLS
concept unique identifier (CUI) C0003873 with a semantic type of
Disease/Disorders. The UMLS provides CUIs for over 130
biomedical ontologies.
For machine learning purposes, the clinical narrative is typically
represented as a vector of features, where the features can be such
as expert-provided terms related to a target disease [16], all
distinct terms (bag-of-words (BOW) [19]) or UMLS concepts [17]
found in a clinical document. A disadvantage of the task-specific
dictionaries is that they are manually tailored by domain experts in
a time-consuming process. While these features have proven
helpful [8][15] , they might not be exhaustive. On the other hand,
the drawback of using all unique terms is that the feature space
becomes very big. A small corpus of clinical narratives may have a
representation of thousands of features. Therefore, different
methods for statistical feature selection to reduce the feature space
[20,21] have been proposed. A range of feature selection methods
are summarized by Joachims [22], Ma & Huang [23], Sayes, Inza,
& Larranaga [24], Zhao et al. [25], and Yang et al. [26].
In this study, we aim to develop methods to automatically
discover RA disease activity at discrete rheumatology clinic visits
based on EMR data. Such an automated method has the potential
to speed up the collection of patient cohorts from the EMR for
further clinical investigation, currently a time-consuming manual
process. We approach the problem as a classification task. NLP
technologies are utilized to analyze the EMR clinical text and
transform it into computable features. In our previous work
[27,28], we (1) explored multiple feature representations of clinical
notes such as user-defined terms, UMLS CUIs [18], BOW, and
word-CUI bigrams, and (2) tested several filter-based feature
selection methods to reduce the dimensionality of the feature space
and improve classification. In this manuscript, our goal is to build
on that work and to investigate algorithms for discovering disease
activity level using EMR data. This work is the first step for future
studies of pharmacogenetic predictors of biologic agent drug
response in large cohort studies harvested from big data EMRs.
All abbreviations used in this paper are listed in Table S6.
Materials and Methods
Materials
The RA EMR cohort used in this study included 5,900 patients
from Partners HealthCare RA case status was assigned based on a
validated algorithm developed at Partners HealthCare that used a
combination of variables extracted from the clinical narrative and
codified EMR data to automatically discover RA cases [15]. The
EMR algorithm has a 0.94 positive predictive value (PPV) for RA
diagnosis with demonstrated portability across two other EMRs
[29]. We also devised a series of filtering criteria to select
informative notes from rheumatology clinic visits from the cohort,
excluding educational notes, telephone notes, and visits to the
infusion center, primary care, or other subspecialists (Consult the
Filtering Criteria S1 for a list of the filtering criteria). Based on
recommended thresholds in clinical trials [30], DAS28 score was
categorized into High (DAS28.5.1), Moderate (DAS28.3.2–5.1),
Low (DAS28$2.6–3.2), and Remission (DAS28,2.6). We used
the four DAS28-derived categories of disease activity as gold
standard labels for the Training Set and Test Set 1 described
below. Lab values were retrieved from a structured EMR database
separate from the database containing the text blob of the clinical
narrative.
Among the RA EMR Cohort, disease activity was quantitatively
measured in 852 RA patients enrolled in longitudinal cohort study,
the BRASS. We selected 2792 notes from visits at rheumatology
clinics from these 852 patients to form the Training Set. Each note
has a DAS28 score and associated CRP and/or ESR lab values,
and MD-estimated DAS scored at the time of the visit (without
laboratory data available). The disease activity labels associated
with each clinical note were automatically assigned by using the
DAS28 score into High, Moderate, Low, or Remission categories.
Among the RA EMR cohort, disease activity was quantitatively
measured using an online disease activity tool for an independent
group of 821 RA patients as part of clinical care at Brigham &
Women’s Hospital. We selected 1749 notes from rheumatology
visits from these 821 patients to form Test Set 1. Each note has a
DAS28 score and associated CRP and/or ESR values, and MD-
estimated DAS scored at the time of the visit (without laboratory
data available). The disease activity labels associated with each
document were automatically assigned by using the DAS28 score
into High, Moderate, Low, or Remission categories following the
same procedure as for the Training Set. To measure the inter-
annotator agreement (IAA) as F1 score [31], two domain experts
reviewed 93 of these clinical notes to classify disease activity into
the four disease activity categories, without knowledge of
laboratory values.
We randomly selected 445 clinical notes for a third group of 445
RA patients (one note per each patient) without structured DAS28
Automatic Prediction of RA Disease Activity
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from the remaining RA EMR cohort to form an independent test
set comprised of notes from regular care to form Test Set 2. Three
domain experts (study rheumatologists) independently reviewed
these notes to assign clinical disease activity labels (High,
Moderate, Low and Remission) based on clinical data in the
notes alone with no additional outside lab values since CRP results
were not available to the clinician at the time of the visit.
Disagreements were resolved in an adjudication step. The IAA for
Moderate and Low categories was consistently low with difficulty
reaching consensus. Thus, reviewers subsequently labeled disease
activity into aggregate Moderate/High or Low/Remission cate-
gories. Some of the notes did not contain enough information for
the domain experts to make a reliable classification, therefore they
were removed. Thus, the final Test Set 2 included 344 notes for
344 RA patients. Test Set 2 is used to test the portability of the
methods for automatic disease activity labeling of notes without
CRP/ESR laboratory data.
Table 1 presents the dataset characteristics.
The study was conducted under an approved Institutional
Review Board (IRB) protocol.
Methods
Figure 1 presents the general flow of our document-level disease
activity prediction process. As most of the information necessary
for assigning a disease activity status is contained in the free text
EMR clinical narrative, we used an open source Apache Software
Foundation NLP System, the clinical Text Analysis and Knowl-
edge Extraction System (cTAKES) [32,33], to discover clinical
named entity mentions (NEs) such as diseases/disorders, signs/
symptoms, anatomical sites, procedures, and medications, along
with their UMLS code, negation status, and context. Each EMR
note is then represented as a vector of features. The multi-
dimensional feature space is reduced using feature selection
methods. This pruned feature space is then combined with lab
values as retrieved from a relation database within the EMR and
used to train and evaluate several classification methods to predict
the disease activity label.
Free Text Features and Feature Selection
In our previous work [27] we tested four sets of features to
represent the clinical narrative text: (1) a user-defined list of terms,
(2) UMLS CUIs, (3) BOWs, and (4) unigrams or word-CUI
bigrams. The user-defined dictionary features (also referred to as
‘‘customized dictionary’’) are entities hand-picked by human
experts (study rheumatologists) through chart review or based on
their expertise and professional experience. Customized features
are usually small in number but their manual generation is a time-
consuming process. In contrast, feature sets 2–4 are generated
automatically and could be large in number requiring space
reduction. We call set 2–4 features ‘‘comprehensive automatic
features’’. UMLS CUI features are medical entity mentions
mapped to a UMLS CUI, e.g. in the example in Figure 1 ‘‘no joint
pain’’ is represented as the negation of a UMLS concept with CUI
C0003862 (-C0003862). BOW features are unordered collections
of words that appear in all notes, ignoring stop words, e.g. the
example in Figure 1 has the following alphabetically ordered
BOW representation – has, joint, pain, patient, this. Word-CUI
bigram features are the two-unit sequence of a CUIs and its
modifier (if such exists in the text). For example, ‘‘severe synovitis’’
is represented as the bigram ‘‘severeC0039103’’. If, on the other
hand, there is no modifier for ‘‘synovitis’’, it is represented as a
unigram ‘‘C0039103’’. To reduce the space of the comprehensive
automatic features, we devised a feature selection pipeline to select
the most informative features which we described in a separate
manuscript [27]. Briefly, the three-step feature selection pipeline is
composed of a frequency cutoff, Chi-squared [34] feature
selection, and the Correlation-based Feature Selection (CFS)
[35] that uses the genetic algorithm [36] to search for an optimal
feature subset. We selected features which had positive chi-square
scores with the class label, ignoring features which had zero chi-
square scores with the class label where zero is a natural threshold
for un-correlated variables. We used the default setting of the
Weka [37] Genetic Algorithm tool: crossover probability as 0.6,
mutation probability as 0.033 and population size as 20.
Lab Values as Features
The ESR/CRP lab values are stored in a structured database
within the EMR and are therefore straightforward to unambig-
uously extract. We used these values as an additional feature in
algorithm development motivated by their relevance in the DAS28
calculation [8,9,38]. These lab values were represented as
numerical values in our feature space. Figure 2 shows that lab
value features (CRP or ESR) are indeed the most informative
feature in terms of the Chi-square score.
Training Selection
In routine practice, it is quite clear when patients have active
inflammation or are in complete remission - the extremes on the
disease activity spectrum. Not surprisingly, disease activity indices
are more accurate for patients with either high or low disease
activity [6]. In Collier et al. [6], the physician-predicted disease
activity was compared with the calculated DAS. Using the
physician-predicted disease activity score as the gold standard,
calculated DAS accuracy was greatest for patients with High
Table 1. Dataset characteristics.
Training Set Test Set 1 Test Set 2
High Disease Activity 506 notes 190 notes
Moderate Disease Activity 966 notes 610 notes
Aggregate High/Moderate Disease Activity 1472 notes 800 notes 133 notes
Low Disease Activity 369 notes 312 notes
Remission Disease Activity 951 notes 637 notes
Aggregate Low/Remission Disease Activity 1320 notes 949 notes 211 notes
Total 2792 notes 1749 notes 344 notes
Agreement MD/DAS28: 0.81 MD/DAS28: 0.87 Inter-annotator agreement: 0.87
doi:10.1371/journal.pone.0069932.t001
Automatic Prediction of RA Disease Activity
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disease activity (68% accuracy) and those in Remission (75%
accuracy), and less accurate for those with Moderate (48%) or Low
disease activity (62%) [6]. By studying the IAA between domain
expert clinical notes review without available laboratory data and
structured DAS-derived labels in the Training Set, we found that
the majority of the discrepancies fell in the Moderate and Low
disease activity categories (19 cases), while the High and Remission
disease activity categories account for only 6 discordances. Figure 3
plots the histogram of the 25 discordant cases.
Therefore, we hypothesized that by removing the Moderate and
Low disease activity documents from the Training Set (albeit not
from the test set), the classifier can learn concepts that are
important in the extreme cases of Remission and High disease
activity and avoid terms from the noisier categories of Moderate
and Low disease activity. Focusing on these informative terms may
not only help classify the extreme cases but also improve the model
performance on the middle boundary sections. Beigman and
Klebanov [39] showed that adding controversial cases in training
could be detrimental to the correct prediction of uncontroversial
cases (‘‘hard case bias’’). Thus, we compared training on the
‘‘extreme’’ High and Remission labels to training on ‘‘all notes’’
labeled with the aggregate High/Moderate and Low/Remission.
Classification Method
We used the following classification algorithms in our experi-
ments: Logistic Regression [40], Naı¨ve Bayes [41], Multilayer
perceptron [42], Support Vector Machines (SVMs) [43,44] with
linear kernel, SVMs with polynomial kernel, SVMs with Pearson
universal kernel [45], and SVMs with Gaussian kernel, all as
implemented in Weka [37].
Logistic Regression directly models the posterior class proba-
bilities by applying a logistic sigmoid function on a linear
combination of the feature vector. Its parameters are usually
estimated by maximum likelihood. Naı¨ve Bayes classifier models
the probability of a class given features by applying Bayes’ theorem
and a strong independence assumption. That is, conditional on the
class, the distributions of the feature variables are independent to
each other. Multilayer perceptron, also known as the neural
network, is a network of multiple layers of nodes in a directed
graph. The network can be trained in a supervised fashion by the
backward propagation of errors. The information of an input
vector will be propagated through the network for output
evaluation. SVMs are supervised learning methods that take a
set of training data and optimize separations by maximizing the
margin between the data categories. SVMs retain input data that
lie on the maximum margin hyperplanes as support vectors to
define the distinguishing criteria for making predictions on new
data. For the data that are not linearly separable in their original
space, SVMs have kernel functions that project the data into other
feature spaces to achieve better separation.
Evaluation
Performance is evaluated using standard metrics. F1 score [31] is
the harmonic mean of recall (R) and precision (P): F1 = (2*P*R)/
(P+R), where recall is (R = TP/(TP+FN)) and precision is (P = TP/
(TP+FP)) where TP is true positives, FN is false negatives, FP is
false positives). Area Under the Receiver Operating Characteristic
Curve (AUC) [46] is a measure of discrimination that can be
viewed as the overall model performance given varied decision
boundaries.
To compare the performance, two baselines were used. Baseline
1 is a linear SVMs model; features are BOWs without FS. Baseline
2 is a linear SVMs model; features are BOWs features and lab
values. BOWs features are traditionally used as baselines for
document classification.
Figure 1. Representation of the processing flow for automatic disease activity labeling. Abbreviations: CUI – Unified Medical Language
System Concept Unique Identifier; cTAKES – clinical Text Analysis and Knowledge Extraction System; LR – Low/Remission disease activity; MH –
Medium/High disease activity; EMR – Electronic Medical Record.
doi:10.1371/journal.pone.0069932.g001
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Test Sets were split into 10 folds. Models were tested across all
folds for measuring the variance of performance.
Results
SVMs with a linear kernel deliver the most robust performance
especially when Lab values were added as a feature. Detailed
results from all experiments can be found in Tables S1, S2, S3, S4,
S5. Figures S1, S2, S3 show the top contributing variables with the
feature sets and their chi-square values.
Table 2 shows results on Test Set 1 using a linear-kernel SVM
model. The best performing model is the linear-kernel SVM
model trained on extremes in the Training Set where the features
are the UMLS CUIs after feature selection and ESR/CRP values.
Its average 10-fold AUC on the test set evaluation was 0.831, with
a standard deviation of 0.0317. Figure 4 shows the distribution of
mis-classified cases from the best performing model. The majority
of the errors are in the Moderate and Low categories, 62% and
20% respectively. We compared the results from this best
performing model with the ones from the other Table 2 models
using DeLong test [47] and found it is significantly better (p-
values,0.05). The ROC curves of these models are shown in
Figure S4.
For the best performing model in Table 2, we examined the
contribution of each feature. The lab value feature is a strong
indicator of disease activity. This fact is further supported by its
Chi-square value (Figure 2). Table 3 compares the feature
contribution given both linear-kernel SVM and Decision Tree
[48], a baseline rule-based classifier. It shows that using only the
lab value feature gets the majority of classifications correct, even
though its effectiveness is not as good as the CUI features. As
expected, the best result combines NLP-based features and Lab
values.
Table 4 shows the results from the portability test. Because the
notes in Test Set 2 do not have associated CRP/ESR lab values,
these missing values are imputed as the global feature mean by
Weka.
Discussion
The best performing disease activity classifier utilizes a
representation of the clinical narrative as UMLS CUIs pruned
by feature selection and combined with lab values from structured
EMR databases. The F1 score of the best model approaches the
human expert agreement. As demonstrated by Collier et al [6] and
Figure 3, most of the discrepancies between rheumatologist ratings
Figure 2. Lab-value and 20 top-ranked CUIs. Their Chi-square values were visualized as bars. Longer bars suggest higher impact. The negative
signs ‘‘-’’ before some of the CUIs suggest negation (CUI – Unified Medical Language System Concept Unique Identifier).
doi:10.1371/journal.pone.0069932.g002
Automatic Prediction of RA Disease Activity
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e69932
of disease activity (without knowledge of ESR or CRP lab results)
and DAS28 occur in the Moderate and Low categories. We
hypothesized that excluding these categories from training (albeit
not from testing) would improve discrimination. As expected,
results did improve (AUC 0.81 to 0.83 in Table 2). Since IAA
between rheumatologists and DAS28 range from 0.81–0.87 when
they do not have results available from ESR or CRP, we
hypothesized that laboratory test results would be strong predictors
of DAS28 categories. We found that adding lab values to the
models improved discrimination from 0.78 to 0.83.
Why is the classification of Low and Moderate disease activity
by machine learning problematic? By studying the concordance
between the DAS28 scores and lab values, we found that these two
values are poorly correlated with the Low and Moderate disease
activity labels. For the 429 mis-classified cases, the scatter plot
between DAS28 and log transformed lab values appears random
(Figure 5, right diagram, Spearman: 0.02 [49]). For the 1320
correctly classified cases, the scatter plot (Figure 5, left diagram)
shows relatively good correlation (Spearman: 0.63).
It is well known that the ESR and/or CRP values are indicators
of disease activity. When the lab value correctly reflects the reality
of the patient’s disease status, especially for the extreme cases, our
model is very accurate. However, if the lab value is less well
correlated with clinical aspects of the DAS28 score as in Low and
Moderate disease activity documents, the model’s performance is
strongly influenced by it. The left diagram in Figure 6 points to a
lab range corresponding to the different disease activity categories.
For the 1320 correctly classified cases, the lab values for the
Moderate/High class and the lab values for the Low/Remission
class can be separated at 1.5 log value (the first quartile of
Figure 3. Histogram of DAS28 scores for 25 discordant cases. These discordant cases are between DAS labels and domain expert labels
among 93 random samples from the Training Set (the remaining 68 cases were concordant).
doi:10.1371/journal.pone.0069932.g003
Table 2. Corpus selection effect on Test set 1 using a linear-kernel SVM model.
Features Training Testing F1 score 6 s AUC 6 s
UMLS CUIs after feature
selection and lab values
High and Low Disease Activity labels
from Training set
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Test Set 1 (10-fold cross-validation)
0.78960.0445 0.831±0.0317
UMLS CUIs after feature
selection and lab values
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Training Set
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Test Set 1 (10-fold cross-validation)
0.74760.0316 0.81060.0297
Baseline 1
Bag-of-words
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Training Set
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Test Set 1 (10-fold cross-validation)
0.73760.0331 0.73260.0348
Baseline 2
Bag-of-words and lab values
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Training Set
Aggregate High/Moderate and Low/
Remission Disease Activity labels from
Test Set 1 (10-fold cross-validation)
0.75060.0265 0.75860.0291
doi:10.1371/journal.pone.0069932.t002
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Moderate/High class meets the third quartile of Low/Remission
class at 1.5 log value). However, for the 429 misclassified cases
there is no such range pattern (Figure 6, right diagram). Among
the 429 errors, given the 1.5 lab boundary, there are 212 notes
whose lab values cross the boundary indicating a disease activity
category not matching the final DAS28. A possible solution to this
problem could be incorporating additional structured codified
data, such as the patient self-reported assessment of global health,
to help balance the impact of lab values. Another approach is to
add a learnable weight for the ESR/CRP feature.
Another possible venue to improve the performance of the
classifier is through new feature engineering that incorporates
domain knowledge. Asserted relations between relevant entity
mentions more precisely represent the details of the clinical events.
For example, an asserted locationOf relation between a sign/
symptom mention and an anatomical site mention such as
‘‘swollen wrists’’ can provide important learnable information for
better understanding of the clinical narrative.
Why does the linear-kernel model yield the best performance?
There could be several explanations. The lab feature is a
dominating feature and by itself has a strong indication of linear
separation (i.e. higher lab values indicate higher disease activity
levels). For the comprehensive feature sets, we applied chi-square
and CFS methods. Chi-square tests and Pearson correlations
which the CFS is based on are both not very sensitive to non-linear
relationships [50,51]. Thus the selected features may be dominat-
ed by variables that are linearly correlated with the label. We have
been working on exploring other statistics that can give balanced
measures for both linear and non-linear correlation [28], so that
our future feature selection pipeline can include both linearly and
non-linearly informative features.
Automatic discovery of document-level disease activity in large
EMR datasets is a critical step towards our overarching goal of
identifying responders and non-responders to biologic agents for
pharmacogenomics research in RA. In the future, we are planning
to integrate the automatically generated document-level disease
activity labels for the clinical visits with the medication start date to
model a general timeline for responders and non-responders.
Limitations
We made efforts to test the approach for portability on
independent previously unseen data (Test Set 1 and Test Set 2).
However, our portability tests come from one institution.
Expanded testing will port the classifier to a different EMR
environment. In order to deploy our disease activity classifier to
other institutions, the document filtering criteria (as described in
Filtering Criteria S1) would need to be tailored to the specific
institution’s EMR and then applied to an RA EMR cohort. To
Table 3. Feature contribution.
SVM with linear kernel Decision Tree
Features F1 score 6 s AUC 6 s F1 score 6 s AUC 6 s
UMLS CUIs 0.74060.039 0.77560.036 0.72260.0602 0.66960.0641
Lab Values 0.73660.0393 0.74860.0300 0.70460.0419 0.67960.0337
UMLS CUIs and Lab Values 0.78960.0445 0.831±0.0317 0.7460.0447 0.71460.0505
doi:10.1371/journal.pone.0069932.t003
Figure 4. Error analysis of the best performing classifier. Out of
429 misclassified cases (using DAS28 derived dichotomous labels as
gold standard), the majority are from the Moderate and Low disease
activity categories.
doi:10.1371/journal.pone.0069932.g004
Table 4. Portability testing.
Features Training Testing F1 score 6 s AUC 6 s
UMLS CUIs after feature
selection and lab values
High and Low Disease Activity
labels from Training set
Aggregate High/Moderate and Low/Remission
Disease Activity labels from Test Set 2 (10-fold
cross-validation)
0.76160.0553 0.78560.0599
UMLS CUIs after feature
selection and lab values
Aggregate High/Moderate and
Low/Remission Disease Activity
labels from Training Set
Aggregate High/Moderate and Low/Remission
Disease Activity labels from Test Set 2 (10-fold
cross-validation)
0.64660.0863 0.74860.0944
doi:10.1371/journal.pone.0069932.t004
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maximize the model’s performance, each document would benefit
from an association with a lab value (either ESR or CRP), though
our model can deal with missing ESR/CRP. In addition, we are in
the process of porting the methodology to discover disease activity
levels for other medical conditions such as Multiple Sclerosis and
Inflammatory Bowel Disease.
Conclusion
In this work we show how within an EMR environment the
output of a comprehensive clinical NLP system in combination
with lab values stored in structured databases can be used to
develop a document-level classifier for the novel phenotype of
Figure 5. Scatter plot of DAS28 scores and log transformed lab values. (Left) Scatter plot of DAS28 scores and log transformed lab values for
1320 correctly classified notes. (Right) Scatter plot of DAS28 scores and log transformed lab values for 429 misclassified notes. The lines are the
regression lines.
doi:10.1371/journal.pone.0069932.g005
Figure 6. Ranges of lab values. (Left) Range of lab values for Moderate/High (MH) disease activity cases vs. Range of lab values for Low/Remission
(LR) disease activity cases among 1320 correctly classified notes. (Right) Range of lab values for Moderate/High (MH) disease activity cases vs. Range
of lab values for Low/Remission (LR) disease activity cases among 429 misclassified notes.
doi:10.1371/journal.pone.0069932.g006
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disease activity in RA. The best performing classifier uses as
features lab values and UMLS CUIs after feature selection. The
classifier is implemented as a linear kernel SVM to achieve results
that are comparable to the human expert agreement. This study is
a building block towards the task of identifying responders and
non-responders of disease treatments in pharmacogenomics
research.
Supporting Information
Figure S1 20 top-ranked user-defined customized dic-
tionary features. Their related Chi-square values were
visualized as bars. Longer bars suggest higher impact.
(TIF)
Figure S2 20 top-ranked unigram and word-CUI bi-
gram features. Their Chi-square values were visualized as bars.
Longer bars suggest higher impact. The negative signs ‘‘-’’ before
some of the CUIs suggest negation. A bigram is formatted as
‘‘CUI_modifier’’ or ‘‘modifier_CUI’’, depending on the order
between CUI and its modifier/noun in real text. The concept
name of each CUI/RxNorm Code is listed after ‘‘|’’. If there is no
nearby modifier or noun word, the CUI is picked up as a unigram,
such as RxNORM ‘‘8640’’ has a preferred term of ‘‘prednisone’’.
(TIF)
Figure S3 20 top-ranked word features. Their related Chi-
square values were visualized as bars. Longer bars suggest higher
impact. ‘‘hapatospleno’’ is the stemmed form of ‘‘hepatospleno-
megaly’’.
(TIF)
Figure S4 ROC curves of five models tested on the Test
set 1. From top to bottom: (1) The linear-kernel SVM model
trained on High and Remission cases of the Training set, using
selected CUI features and lab values; (2) The RBF-kernel SVM
model trained on High and Remission cases of the Training set,
using selected CUI features and lab values; (3) The linear-kernel
SVM model trained on all notes of the Training set, using selected
CUI features and lab values; (4) Baseline system 2, which is a
linear kernel SVM model on all BOW features with lab values; (5)
Baseline system 1, which is a linear kernel SVM model on all
BOW features without lab values.
(TIF)
Filtering Criteria S1 The filtering criteria were developed
iteratively as we reviewed sets of charts and were applied to the test
sets. No filtering criteria were applied to the training set.
(DOCX)
Table S1 Number of features for a user-defined customized
dictionary, Unified Medical Language System Concept Unique
Identifier (UMLS CUI), Word, and Word_CUI bigram on the
Training Set.
(DOCX)
Table S2 Portability test for all classifiers trained on Unified
Medical Language System Concept Unique Identifier (UMLS
CUI) features: using lab feature vs. no lab features.
(DOCX)
Table S3 Portability test for all classifiers trained on user-defined
customized dictionary features: using lab feature vs. no lab
features.
(DOCX)
Table S4 Portability test for all classifiers trained on word
features: using lab feature vs. no lab features.
(DOCX)
Table S5 Portability test for all classifiers trained on word-CUI
bigram features: using lab feature vs. no lab features.
(DOCX)
Table S6 Table of abbreviations.
(DOCX)
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